Current management of opioid-related side effects

ONCOLOGY

Volumn 15, Issue 1, 2001, Pages 61-73

  O'Mahony, Sean ^a   Coyle, Nessa ^b   Payne, Richard ^b  

^a Calvary Hospital   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; LAXATIVE; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; OPIATE RECEPTOR;

CHEMICALLY INDUCED DISORDER; COGNITION; COMPARATIVE STUDY; CONSTIPATION; HUMAN; METABOLISM; NAUSEA; REVIEW; RISK ASSESSMENT; VOMITING;

ANALGESICS, OPIOID; ANTIEMETICS; ANTIPSYCHOTIC AGENTS; CATHARTICS; CONSTIPATION; HUMANS; NAUSEA; NEUROBEHAVIORAL MANIFESTATIONS; RECEPTORS, OPIOID; RISK ASSESSMENT; VOMITING;

EID: 0035229016     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Payne R, Mathias S, Pasta D, et al: Quality of life and cancer pain. J Clin Oncot 16(4):1588-1593, 1998.
2. Ahmedzai S, Brooks D: Transdermal fentanyl vs sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 13(5):254-261, 1997.
3. Mercadante S, Salvaggio L, Dardanoni G, et al: Dextropropoxyphene vs morphine in opioidnaive cancer patients with pain. J Pain Symptom Manage 15(2):76-81, 1998.
4. Broomhead A, Kerr R, Tester W, et al: Comparison of once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. J Pain Symptom Manage 14(2):63-73, 1997.
5. Wallenstein SL, Kaiko RF; Rogers AG, et al: Clinical analgesic assay of sublingual buprenorphine and intramuscular morphine. NIDA Res Monogr 41:288-293, 1982.
6. Heiskanen T, Kalso E: Controlled release oxycodone and morphine in cancer-related pain. Pain 73(1):37-45, 1997.
7. Wallenstein SL, Houde RW, Portenoy R, et al: Clinical analgesic assay of repeated and single doses of heroin and hydromorphone. Pain 41(1):5-13, 1990.
8. Beaver WT, Wallenstein SL, Houde RW, et al: Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer. J Clin Pharmacol 17(4): 186-198, 1977.
9. Coda BA, O'Sullivan B, Donaldson G, et al: Comparative efficacy of patient controlled administration of morphine, hydromorphone, or sulfentanil for the treatment of oral mucositis pain following bone marrow transplantation. Pain 72(3):333-346, 1997.
10. Chemy NJ, Chang V, Frager G, et al: Opioid pharmacotherapy in the management of cancer pain, a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 76(7): 1283-1293, 1995.
11. Klotz U, McHorse T, Wilkinson GR, et al: The effect of cirrhosis on the disposition and elimination of meperidine in man. Clin Pharmacol Ther 16:667-675, 1974.
12. Pond S, Tong T, Benowitz N et al: Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects. Clin Pharmacol Ther 30:183-188, 1981.
13. Inturrisi CE, Umans JG: Meperidine biotransformation and central nervous system toxicity in animals and humans, in Foley KM, Inturrisi CE (eds): Advances in Pain Research and Therapy, pp 143-153. New York, Raven Press, 1986.
14. Kaiko R, Foley K, Grabinski PY, et al: Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 13:180-185, 1983.
15. Gibson TP, Giacomini KM, Briggs W, et al: Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient. Clin Pharmacol Ther 27:665-670, 1980.
16. Ventafridda V, Bianchi M, Ripamonti C, et al: Studies of the effects of antidepressant drugs on the antinociceptive action of morphine and on the plasma morphine in rat and man. Pain 43(2): 155-162, 1990.
17. Decks SG, Smith M, Holodniy M, et al: HIV-1 Protease inhibitors, a review for clinicians. JAMA 2:277, 1997.